As FIP is an immune complex disease (Addie et al., 2003; Berry, 2001), one can speculate that suppressing the expression of proteins such as IAP and TFF‐3 and stimulating the expression of proteins such as I‐FABP may affect disease progression. This evidence concerns the gene FABP2 and type III hypersensitivity disease.